Should I buy or sell Blueprint Medicines stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BPMC shares. View BPMC analyst ratings or view top-rated stocks .

What is Blueprint Medicines' stock price target for 2024?

14 equities research analysts have issued 1-year price objectives for Blueprint Medicines' stock. Their BPMC share price targets range from $43.00 to $115.00. On average, they anticipate the company's share price to reach $85.43 in the next twelve months. This suggests that the stock has a possible downside of 5.2%. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts .

How have BPMC shares performed in 2024?

Blueprint Medicines' stock was trading at $92.24 on January 1st, 2024. Since then, BPMC shares have decreased by 2.3% and is now trading at $90.09. View the best growth stocks for 2024 here .

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 4,370,000 shares, a decline of 15.1% from the March 15th total of 5,150,000 shares. Based on an average trading volume of 786,700 shares, the days-to-cover ratio is presently 5.6 days. View Blueprint Medicines' Short Interest .

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BPMC earnings forecast .

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) issued its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, beating analysts' consensus estimates of ($2.04) by $0.22. The biotechnology company earned $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 191.56% and a negative net margin of 203.30%. Blueprint Medicines's quarterly revenue was up 85.5% on a year-over-year basis. During the same quarter last year, the company earned ($2.65) EPS.

What ETFs hold Blueprint Medicines' stock?

ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , Invesco Biotechnology & Genome ETF (PBE) , WisdomTree BioRevolution Fund (WDNA) , Virtus LifeSci Biotech Products ETF (BBP) , BlackRock Future Health ETF (BMED) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , SPDR S&P Biotech ETF (XBI) and Harbor Corporate Culture Small Cap ETF (HAPS) .

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com . Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD) , NVIDIA (NVDA) , AbbVie (ABBV) , Micron Technology (MU) , Pfizer (PFE) , Gilead Sciences (GILD) , QUALCOMM (QCOM) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR) .

When did Blueprint Medicines IPO?

Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a variety of retail and institutional investors. Top institutional investors include Diversified Trust Co (0.02%) and Clarus Wealth Advisors (0.00%). Insiders that own company stock include Ariel Hurley , Christina Rossi , Christopher K Murray , Debra Durso-Bumpus , Fouad Namouni , George Demetri , Jeffrey W Albers , Kate Haviland , L Becker Hewes , Mark Alan Goldberg , Michael Landsittel , Percy H Carter and Tracey L Mccain . View institutional ownership trends .

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BPMC

Blueprint Medicines (BPMC) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free BPMC Stock Alerts

$88.92

+0.54 (+0.61%)

(As of 03:58 PM ET)

Compare

Today's Range: $86.56
▼
$91.76
50-Day Range: $73.17
▼
$99.79
52-Week Range: $43.89
▼
$101.00

Volume: 571,127 shs
Average Volume: 762,414 shs
Market Capitalization: $5.44 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $85.43

Get Blueprint Medicines alerts:

Blueprint Medicines MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 5.2% Downside
$85.43 Price Target
Short Interest: Healthy
7.14% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 3 Articles This Week
Insider Trading: Selling Shares
$10.36 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($5.42) to ($2.92) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.79 out of 5 stars

Medical Sector

836th out of 919 stocks

Pharmaceutical Preparations Industry

379th out of 415 stocks

2.3

Analyst's Opinion

Consensus Rating
Blueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 8 buy ratings, 2 hold ratings, and 3 sell ratings.
Amount of Analyst Coverage
Blueprint Medicines has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
7.14% of the outstanding shares of Blueprint Medicines have been sold short.
Short Interest Ratio / Days to Cover
Blueprint Medicines has a short interest ratio ("days to cover") of 5.6.
Change versus previous month
Short interest in Blueprint Medicines has recently decreased by 15.15%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Blueprint Medicines does not currently pay a dividend.
Dividend Growth
Blueprint Medicines does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BPMC.

2.2

News and Social Media Coverage

News Sentiment
Blueprint Medicines has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Blueprint Medicines this week, compared to 5 articles on an average week.
Search Interest
Only 1 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Blueprint Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,361,913.00 in company stock.
Percentage Held by Insiders
Only 3.88% of the stock of Blueprint Medicines is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Blueprint Medicines are expected to grow in the coming year, from ($5.42) to ($2.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Blueprint Medicines is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Blueprint Medicines is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Blueprint Medicines has a P/B Ratio of 41.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

If You Missed Out On The AI Boom, Take These 3 Steps

About Blueprint Medicines Stock (NASDAQ:BPMC)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

BPMC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BPMC Stock News Headlines

April 2, 2024 | insidertrades.com

Blueprint Medicines Co. (NASDAQ:BPMC) CFO Michael Landsittel Sells 5,000 Shares

March 27, 2024 | insidertrades.com

Jeffrey W. Albers Sells 11,033 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 23, 2024 | insidertrades.com

Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $2,188,371.44 in Stock

March 20, 2024 | insidertrades.com

Blueprint Medicines Co. (NASDAQ:BPMC) CFO Michael Landsittel Sells 13,734 Shares

April 18, 2024 | prnewswire.com

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

April 11, 2024 | prnewswire.com

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics

April 11, 2024 | americanbankingnews.com

Blueprint Medicines (NASDAQ:BPMC) Rating Reiterated by JMP Securities

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | markets.businessinsider.com

Decoding 6 Analyst Evaluations For Blueprint Medicines

April 10, 2024 | markets.businessinsider.com

Blueprint Medicines Buy Rating: Promising BLU-222 Efficacy and Strong Financial Outlook

April 4, 2024 | prnewswire.com

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 29, 2024 | finance.yahoo.com

Blueprint Medicines Corporation (NASDAQ:BPMC): When Will It Breakeven?

March 21, 2024 | investing.com

Blueprint Medicines executive sells stock worth over $399k

March 21, 2024 | nasdaq.com

First Week of May 17th Options Trading For Blueprint Medicines (BPMC)

March 16, 2024 | finance.yahoo.com

BPMC Apr 2024 90.000 put

March 15, 2024 | finance.yahoo.com

Blueprint Medicines Corp's Chief Commercial Officer Sells Company Shares

March 15, 2024 | finance.yahoo.com

BPMC Apr 2024 45.000 put

March 4, 2024 | finance.yahoo.com

BPMC Apr 2024 120.000 call

March 4, 2024 | finance.yahoo.com

BPMC Dec 2024 115.000 call

March 4, 2024 | finance.yahoo.com

BPMC Jun 2024 115.000 call

March 3, 2024 | finance.yahoo.com

BPMC Mar 2024 100.000 put

February 26, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Blueprint Medicines on Strong Ayvakit Clinical Performance and Promising Pipeline

February 26, 2024 | markets.businessinsider.com

Blueprint Medicines Receives Sell Rating Amidst Modest Polypharmacy Reduction and Negative Share Price Projections

February 26, 2024 | markets.businessinsider.com

Blueprint Medicines: Sell Rating Justified by Gavreto Divestiture and Strategic Shift

February 24, 2024 | msn.com

Blueprint Medicines (BPMC) Price Target Increased by 11.02% to 99.12

February 23, 2024 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on Blueprint Medicines (BPMC)

See More Headlines

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/15/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BPMC
CUSIP: N/A
CIK: 1597264
Web: www.blueprintmedicines.com
Phone: (617) 374-7580
Fax: N/A
Employees: 655
Year Founded: 2011

Price Target and Rating

Average Stock Price Target: $85.43
High Stock Price Target: $115.00
Low Stock Price Target: $43.00
Potential Upside/Downside: -3.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($8.36)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-506,980,000.00
Net Margins: -203.30%
Pretax Margin: -202.91%
Return on Equity: -191.56%
Return on Assets: -45.25%

Debt

Debt-to-Equity Ratio: 1.60
Current Ratio: 3.76
Quick Ratio: 3.66

Sales & Book Value

Annual Sales: $249.38 million
Price / Sales: 21.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.15 per share
Price / Book: 41.11

Miscellaneous

Outstanding Shares: 61,200,000
Free Float: 58,825,000
Market Cap: $5.41 billion
Optionable: Optionable
Beta: 0.63

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Ms. Kathryn Haviland (Age 48)
President, CEO & Director
Comp: $1.17M
Mr. Alexis A. Borisy A.M. (Age 52)
Co-Founder & Director
Comp: $50k
Mr. Michael Landsittel (Age 52)
Chief Financial Officer
Comp: $785.36k
Ms. Christina Rossi (Age 47)
Chief Operating Officer
Comp: $875.22k
Ms. Tracey L. McCain Esq. (Age 56)
Executive VP, Chief Legal & Compliance Officer and Secretary
Comp: $764.9k
Dr. Fouad Namouni M.D. (Age 55)
President of Research & Development
Comp: $916.4k
Ms. Ariel Hurley (Age 50)
Senior VP, Finance & Principal Accounting Officer
Dr. Christopher K. Murray Ph.D. (Age 60)
Senior VP of Technical Operations and Chief Technical Operations & Quality Officer
Comp: $338.37k
Dr. Percy H. Carter M.B.A. (Age 53)
Ph.D., Chief Scientific Officer
Comp: $761.15k
Jenna Cohen
Senior Director & Head of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BPMC Stock Analysis - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 sell ratings, 2 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BPMC shares.
View BPMC analyst ratings or view top-rated stocks.
What is Blueprint Medicines' stock price target for 2024?: 14 equities research analysts have issued 1-year price objectives for Blueprint Medicines' stock. Their BPMC share price targets range from $43.00 to $115.00. On average, they anticipate the company's share price to reach $85.43 in the next twelve months. This suggests that the stock has a possible downside of 5.2%.
View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts.
How have BPMC shares performed in 2024?: Blueprint Medicines' stock was trading at $92.24 on January 1st, 2024. Since then, BPMC shares have decreased by 2.3% and is now trading at $90.09.
View the best growth stocks for 2024 here.
Are investors shorting Blueprint Medicines?: Blueprint Medicines saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 4,370,000 shares, a decline of 15.1% from the March 15th total of 5,150,000 shares. Based on an average trading volume of 786,700 shares, the days-to-cover ratio is presently 5.6 days.
View Blueprint Medicines' Short Interest.
When is Blueprint Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BPMC earnings forecast.
How were Blueprint Medicines' earnings last quarter?: Blueprint Medicines Co. (NASDAQ:BPMC) issued its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, beating analysts' consensus estimates of ($2.04) by $0.22. The biotechnology company earned $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 191.56% and a negative net margin of 203.30%. Blueprint Medicines's quarterly revenue was up 85.5% on a year-over-year basis. During the same quarter last year, the company earned ($2.65) EPS.

What ETFs hold Blueprint Medicines' stock?: ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco Biotechnology & Genome ETF (PBE), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Products ETF (BBP), BlackRock Future Health ETF (BMED), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI) and Harbor Corporate Culture Small Cap ETF (HAPS).
What is Kate Haviland's approval rating as Blueprint Medicines' CEO?: 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.
What other stocks do shareholders of Blueprint Medicines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).
When did Blueprint Medicines IPO?: Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Blueprint Medicines' major shareholders?: Blueprint Medicines' stock is owned by a variety of retail and institutional investors. Top institutional investors include Diversified Trust Co (0.02%) and Clarus Wealth Advisors (0.00%). Insiders that own company stock include Ariel Hurley, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Mark Alan Goldberg, Michael Landsittel, Percy H Carter and Tracey L Mccain.
View institutional ownership trends.
How do I buy shares of Blueprint Medicines?: Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BPMC) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Blueprint Medicines (BPMC) Stock Price, News & Analysis

Blueprint Medicines MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Blueprint Medicines Stock (NASDAQ:BPMC)

BPMC Stock Price History

BPMC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

BPMC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™